Figure S1:
Banff components of chronic lesions in the last biopsy before rituximab in the R and NR cohorts:
a) cg = allograft glomerulopathy, b) ci = interstitial fibrosis, c) ct = tubular atrophy, d) cv = vascular fibrous intimal thickening. There were no significant differences between groups according to Likelihood Ratio Chi- Quadrat test.
a + b
c + d
Table S1: Individual clinical charts of all patients included in the study;
Abbreviations: autosomal dominant polycystic kidney disease (ADPKD), diabetic nephropathy (diabetic NP), focal and segmental glomerulosclerosis (FSGS), glomerulonephritis (GN), membranoproliferative glomerulonephritis (MPGN), calcineurin inhibitor toxicity (CNI-Tox), reflux nephropathy (Reflux-NP), rapidly progressive glomerulonephritis (RPGN), B=basiliximab, T=tacrolimus, M=mycophenolate mofetil, St=steroids; PS=plasmapheresis (3-4 per patient).
Patient Sex (m) (f)
Age (yr)
Tx Age (months) / Living (l) / Deceased (d) donor / regraft (r)
Renal disease
eGFR / diuresis at
rituximab (ml/min / ml)
Concomitant Findings in the
index biopsy
Maximal proteinuria
(mg/24 h)
Initial immuno- suppression
(IS) at tx
Non responders
1 f 49 4.3 / d Reflux-
nephropathia 28 / 2500 Borderline 380 B, T, M, St, PS
2 f 31 0.3 / d / r Pyelonephritis 13 / 1000 1040 B, T, M, St
3 m 34 6.1 / d Nephro-
nophthisis 12 / 3500 380 B, C, M, St
4 m 29 8.1/ d Chronic GN 28 / 2000 Membranous GN 4.400 B, C, M, St
5 m 18 47.4 / l Unknown 22 / 2000 2310 B, C, M, St
6 f 36 38.2 / d
Mesangio- proliferative GN
17 / 1450 4600 B, T, M, St
7 m 38 5.7/ d
MPGN, CNI- toxicity after heart
transplantation
26 / 1040 Borderline 100 B, T, M, St
8 f 31 187.9 / d RPGN 14 / 1500 9000 B, T, St
9 m 35 1.4/ d / r Pyelonephritis 24 / 600 TCMR 2a 1300 B, T, M, St
10 m 42 28.5 / l Diabetic NP 19 / 2500 4100 B, T, M, St
Responders
11 f 22 57.8 / l Reflux-
nephropathia 27 / 2000 790 B, C, M, St
12 f 48 52.3 / d ADPKD 41 / 2500 180 B, C, M, St
13 m 39 7.1 / d Diabetic NP 39 / 2400 TCMR 2 a 100 B, T, M, St
14 f 41 63.0 / d FSGS 17 / 1810 TCMR 1a 150 B, C, St
15 m 32 62.0 / d Unknown 43 / 3500 1230 B, C, M, St
16 f 48 5.2/ d Chronic GN 27 / 2500
Thrombotic microangiopathy, borderline
1400 B, T, M, St
17 f 40 2.2/ d / r Nephro-
nophthisis 32 / 2300 210 B, T, M, St;
ATG and IVIG
18 m 26 74.8 / l / r IgA-GN 33 / 2100 borderline 1800 T, M, St
19 m 53 144.8 / l / r Chronic GN 62 / 3100 190 B, C, M, St
20 m 45 243.3 / d Diabetic NP 25 / 3100 760 B, C, M, St
Table S2: Detailed features of AMR in biopsies of patients receiving treatment and HLA DSAs with antigen specificities
Abbreviations: I = indication, R = routine, neg = negative, pos = positive; n. a. = not applicable.
Patient I or R biopsy
g score
Ptc score
C4d PTC score
De novo DSA
Cg score
Antigen- specificity of
DSA
DSA detectable in follow-up Non responders
1 I 1 2 1 neg 0
2 I 1 1 0 pos 0 A31, DQ3 Yes
3 R 2 1 0 neg 0
4 I 3 3 0 pos 0 A24 Yes
5 R 1 1 1 n. a. 1 n. a.
6 R 3 2 1 n. a. 3 n. a.
7 I 1 0 1 neg 1
8 R 0 0 2 pos 2 A24, DQ5 Yes
9 I 0 1 1 neg 0
10 I 2 1 0 n. a. 2 n. a.
Responders
11 I 0 2 3 neg 0
12 I 2 0 0 pos 1 DQ2 No
13 R 1 2 0 neg 0
14 I 0 2 3 n. a. 0 n. a.
15 I 0 1 0 pos 3 DQ7 No
16 R 0 2 0 pos 0 DR4 No
17 I 0 1 3 neg 0
18 I 0 2 3 pos 3 A2 Yes
19 I 2 0 1 pos 1 DQ7 Yes
20 I 3 0 0 pos 3 DQ5, DQ6 Yes
